SRD5A2 has clinical relevance in benign prostatic hyperplasia, prostate cancer and other androgen-mediated conditions. In this Review, the authors describe the complementary roles of α-blockers for rapid symptom relief and 5α-reductase inhibitors for disease modification and progression risk reduction in benign prostatic hyperplasia and the potential of targeting SRD5A2 in other androgen-driven disorders.
- Zongwei Wang
- Boqing Gu
- Aria F. Olumi